Overview of the Development and Use of Akt Inhibitors in Prostate Cancer.
Akt
Capivasertib
Ipatasertib
PTEN
castration resistance
prostate cancer
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
29 Dec 2021
29 Dec 2021
Historique:
received:
04
12
2021
revised:
23
12
2021
accepted:
24
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
Deregulation of the PI3K-Akt-mTOR pathway plays a critical role in the development and progression of many cancers. In prostate cancer, evidence suggests that it is mainly driven by PTEN loss of function. For many years, the development of selective Akt inhibitors has been challenging. In recent phase II and III clinical trials, Ipatasertib and Capivasertib associated with androgen deprivation therapies showed promising outcomes in patients with metastatic castration-resistant prostate cancer and PTEN-loss. Ongoing trials are currently assessing several Akt inhibitors in prostate cancer with different combinations, at different stages of the disease.
Identifiants
pubmed: 35011901
pii: jcm11010160
doi: 10.3390/jcm11010160
pmc: PMC8745410
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Drug Resist Updat. 2002 Dec;5(6):234-48
pubmed: 12531180
Biochem J. 2002 Sep 15;366(Pt 3):729-36
pubmed: 11971763
Int J Cancer. 2007 Oct 1;121(7):1424-32
pubmed: 17551921
Ann Oncol. 2020 May;31(5):619-625
pubmed: 32205016
Cancer Res. 2006 Aug 1;66(15):7783-92
pubmed: 16885382
J Biol Chem. 2015 Jan 30;290(5):2759-68
pubmed: 25527506
J Cell Mol Med. 2005 Jan-Mar;9(1):59-71
pubmed: 15784165
Genes Cancer. 2010 Dec;1(12):1170-7
pubmed: 21779440
Br J Cancer. 2013 Oct 1;109(7):1711-6
pubmed: 24008662
Transl Oncogenomics. 2016 Feb 21;7(Suppl 1):33-49
pubmed: 26917948
Curr Cancer Drug Targets. 2009 Mar;9(2):237-49
pubmed: 19275762
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Prostate Cancer Prostatic Dis. 2005;8(2):108-18
pubmed: 15724144
Clin Cancer Res. 2019 Feb 1;25(3):928-936
pubmed: 30037818
Nat Rev Clin Oncol. 2013 Mar;10(3):143-53
pubmed: 23400000
Clin Cancer Res. 2010 Jun 1;16(11):3057-66
pubmed: 20501622
Appl Immunohistochem Mol Morphol. 2011 Mar;19(2):173-83
pubmed: 20930614
Urol Oncol. 2020 Mar;38(3):79.e15-79.e22
pubmed: 31522863
Mod Pathol. 2016 Aug;29(8):904-14
pubmed: 27174589
Front Oncol. 2015 Feb 16;5:24
pubmed: 25763354
Cancer Cell. 2011 May 17;19(5):575-86
pubmed: 21575859
J Clin Oncol. 2021 Jan 20;39(3):190-201
pubmed: 33326257
Int J Cancer. 2003 Nov 20;107(4):676-80
pubmed: 14520710
J Biol Chem. 2005 Sep 30;280(39):33558-65
pubmed: 16061480
Endocr Relat Cancer. 2013 May 20;20(3):R83-99
pubmed: 23456430
Oncogene. 2005 Nov 14;24(50):7455-64
pubmed: 16288292
Oncogene. 2005 Nov 14;24(50):7493-501
pubmed: 16288296
Clin Cancer Res. 2011 Oct 15;17(20):6563-73
pubmed: 21878536
Curr Pharm Des. 2010 Jan;16(1):34-44
pubmed: 20214616
Cancer Cell. 2011 Jun 14;19(6):792-804
pubmed: 21620777
J Genet Genomics. 2015 Jul 20;42(7):343-53
pubmed: 26233890
Br J Cancer. 2010 Feb 16;102(4):678-84
pubmed: 20104229
Curr Genomics. 2007 Aug;8(5):271-306
pubmed: 19384426
Lancet. 2021 Jul 10;398(10295):131-142
pubmed: 34246347
Cancer Res. 1999 Sep 1;59(17):4291-6
pubmed: 10485474